



Assessment of existing anthropometric indices for screening sarcopenic obesity in older adults

Jin Eui Kim^{1†}, Jimi Choi^{2†}, Miji Kim^{3*} and Chang Won Won^{4*}

¹Department of Biomedical Science and Technology, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

²Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University, Seoul 02841, Republic of Korea

³Department of Biomedical Science and Technology, College of Medicine, East-West Medical Research Institute, Kyung Hee University, Seoul 02447, Republic of Korea

⁴Department of Family Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea

(Submitted 21 December 2021 – Final revision received 25 April 2022 – Accepted 31 May 2022 – First published online 17 June 2022)

Abstract

Sarcopenic obesity is defined as the presence of high fat mass and low muscle mass combined with low physical function, and it is closely related with the onset of cardiovascular diseases (CVD). The existing anthropometric indices, which are being utilised in clinical practice as predictors of CVD, may also be used to screen sarcopenic obesity, but their feasibility remained unknown. Using cross-sectional data of 2031 participants aged 70–84 years (mean age, 75.9 ± 3.9 years; 49.2 % women) from the Korean Frailty and Aging Cohort Study, we analysed the association of anthropometric indices, including body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR) and weight-adjusted waist index (WWI) with sarcopenic obesity. Body composition was measured using dual-energy X-ray absorptiometry. Higher WWI, WHtR and WC quartiles were associated with higher risk of sarcopenic obesity; the odds ratio (OR) of sarcopenic obesity were highest in the fourth quartile of the WWI (OR: 10.99, 95 % CI: 4.92–24.85, $P_{\text{for trend}} < 0.001$). WWI provided the best diagnostic power for sarcopenic obesity in men (area under the receiver operating characteristic curve: 0.781, 95 % CI: 0.751–0.837). No anthropometric indices were significantly associated with sarcopenic obesity in women. WWI was the only index that was negatively correlated with physical function in both men and women. WWI showed the strongest association with sarcopenic obesity, defined by high fat mass and low muscle mass combined with low physical function only in older men. No anthropometric indices were associated with sarcopenic obesity in older women.

Keywords: Anthropometry; Sarcopenia; Obesity; Ageing; Body composition

Sarcopenic obesity is the coexistence of sarcopenia and obesity, which is characterised by age-related changes in body composition, decreased muscle mass, increased fat mass and decreased muscle strength and physical performance⁽¹⁾. It is a common problem in older adults that results in physical disability as well as increased cardiovascular diseases (CVD) morbidity and mortality^(2–4). While earlier diagnosis and treatment is imperative, sarcopenic obesity lacks a standardised diagnostic criterion and has traditionally been defined as low muscle mass and high-fat mass^(5,6). Dual-energy X-ray absorptiometry (DXA), MRI and CT are the most precise and accurate methods for measuring body composition; however, these methods have several limitations in clinical practice. They are expensive and time consuming; furthermore, CT is potentially hazardous because of

radiation exposure^(7,8). More importantly, such equipment lacks portability, which makes it difficult to utilise them in extramural care settings. Therefore, it is crucial to develop a method to diagnose sarcopenic obesity in diverse settings while keeping in mind factors such as cost-effectiveness, time taken and safety.

Anthropometry is a simple and practical method to estimate body composition⁽⁹⁾, and there are several anthropometric indices that have been used widely in epidemiologic studies. The global standard to define obesity is based on body mass index (BMI); waist circumference (WC) and waist-to-height ratio (WHtR) were developed for indicators of abdominal obesity. Those anthropometric indices are strongly associated with the onset of CVD^(10–13), and CVD is significantly associated with sarcopenic obesity. This may imply the possibility of

Abbreviations: ASM, appendicular skeletal muscle mass; DXA, dual-energy X-ray absorptiometry; KFACS, Korean Frailty and Aging Cohort Study; SPPB, Short Physical Performance Battery; WC, waist circumference; WHtR, waist-to-height ratio; WWI, weight-adjusted waist index.

* **Corresponding authors:** Miji Kim, email mijjak@khu.ac.kr; Chang Won Won, email chunwon62@naver.com

† These authors contributed equally to this work as the first co-authors.

anthropometric indices for screening sarcopenic obesity. However, BMI has shown a J-shaped relationship with CVD mortality, which resulted in the obesity paradox^(14–16), possibly because of its inability to discriminate muscle mass from fat mass^(17,18). In other words, BMI cannot reflect low muscle mass and high fat mass simultaneously. After the studies revealed that abdominal fat, especially visceral fat, is strong predictor of all-cause and CVD mortality^(19,20), WC and WHtR were proposed in order to overcome the limitation BMI. WC and WHtR had shown a significantly higher association with CVD mortality compared with BMI; however, similar obesity paradox phenomenon was observed⁽²¹⁾. In addition, a recent study suggested a high correlation among WC, WHtR and BMI⁽²²⁾, which represents that high WC and WHtR may also be due to high muscle mass, not solely by high-fat mass. Therefore, the adequacy of anthropometric indices as independent indicators of sarcopenic obesity is still not clear and has to be tested before clinical application. At the same time, a development of new anthropometric indices that can reciprocally reflect muscle mass and fat mass is needed.

In 2018, a new anthropometric index called the weight-adjusted waist index (WWI), which standardised WC for weight, was developed to overcome the shortcomings of existing anthropometric indices⁽²³⁾. The study showed that WWI had a relatively consistent and linear relationship with both CVD morbidity and mortality. More recently, WWI was shown to discriminate muscle mass from fat mass as it showed a negative association with muscle mass and a positive association with fat mass in older adults⁽²⁴⁾, suggesting WWI as a possible indicator of sarcopenic obesity. Along with the change in muscle mass, other components that are proposed to diagnose sarcopenia are muscle strength and physical performance^(25–28); however, not only the association of WWI with muscle strength and physical performance has not yet been determined but also the studies regarding existing anthropometric indices and physical function are limited^(29,30).

In this study, we aimed to analyse the association of different anthropometric indices, including BMI, WC, WHtR and WWI, with sarcopenic obesity to compare their feasibility for screening sarcopenic obesity in community-dwelling older adults.

Methods

Study population

The Korean Frailty and Aging Cohort Study (KFACS) is a nationwide multicentre cohort study that was primarily designed to assess the frailty status of community-dwelling older adults in South Korea. The participants were sex- and age-stratified community residents recruited from urban and rural areas around ten centres who were ambulatory with or without walking aids. The age ratio was 6:5:4 for age 70–74, 75–79 and 80–84 years, respectively, and the sex ratio was 1:1. Followed by the suggestion from the frailty consensus⁽³¹⁾, the starting age of the KFACS was set from 70. The participants over 85 years were excluded due to their difficulty of centre visits and follow-up surveys; the advanced age over 85 years also had a higher probability of interrupting the identification of physical frailty-associated risk

factors. Overall, the inclusion criteria of the participant were age 70–84 years, currently living in the community, having no problem with communication and no prior diagnosis of dementia. The baseline study comprised face-to-face interviews, health examinations and laboratory tests with a total of 3013 participants. Among the total participants, 2403 underwent body composition measurement with DXA in eight university hospitals and 610 with bioelectrical impedance analysis in two community centres. For this study, those who underwent bioelectrical impedance analysis were excluded because of possible systematic bias between DXA and bioelectrical impedance analysis⁽³²⁾. The final analysis included 2031 participants after excluding 321 participants who had artificial joints, pins, plates or other types of metal objects in any part of their bodies, as metal implants could have affected the measurement accuracy of appendicular skeletal muscle mass (ASM) or percentage of body fat⁽³³⁾, and fifty-one participants who had missing data for the diagnostic criteria of sarcopenic obesity. The details of the KFACS protocol have been described previously⁽³⁴⁾.

Ethics

The KFACS protocol was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects/patients were approved by the Institutional Review Board of the Clinical Research Ethics Committee of the Kyung Hee University Medical Center. Written informed consent was obtained from all participants (IRB number: 2015-12-103). This study was approved as an exempt from the Institutional Review Board review (IRB number: 2021-02-021).

Anthropometric measurements

The height, weight and WC of all the participants were recorded. The height and WC were measured to the nearest 0.1 cm, and weight was measured to the nearest 0.1 kg. BMI was calculated as weight (kg) divided by the square of the height (m²). WC (cm) was measured at the midpoint between the lower end of the last rib and the upper ridge of the iliac crest. WHtR was calculated as WC (cm) divided by height (cm)⁽³⁵⁾, and WWI was calculated as WC (cm) divided by the square root of the weight ($\sqrt{\text{kg}}$). Details regarding the derivation of WWI have been described in a previous study⁽²³⁾.

Body composition measurements

ASM and percentage of body fat were measured using DXA (Lunar, GE Healthcare, Madison, WI; Hologic DXA, Hologic Inc.). The participants were asked to remove all metal accessories before the scan and lie in a supine position on the scanner table with their limbs placed parallel to their bodies, according to the manufacturer's protocol. ASM was calculated as the sum of the lean masses of the right and left arms and legs. ASM index was defined as ASM/height² (kg/m²)⁽⁶⁾. Our laboratory assessment of forty volunteers with repositioning between scans demonstrated that the coefficients of variation for whole-body composition were < 2.5 %.



Physical function measurements

Muscle strength. Muscle strength was evaluated by grip strength and measured using a digital handgrip dynamometer (T.K.K.5401; Takei Scientific Instruments Co. Ltd). The participants were asked to stand upright, place their shoulder in a neutral position with both arms fully extended and hold the dynamometer for 3 s with maximum strength. The strength was measured twice for each hand at 3-min intervals. The best records for each hand were rounded to the nearest 0.1 kg⁽³⁶⁾.

Physical performance. Physical performance was evaluated by 4-m usual gait speed, the five-times sit-to-stand test and the Short Physical Performance Battery (SPPB). The 4-m usual gait speed was measured using an automatic gait speed meter (Dynamicphysiology), with acceleration and deceleration phases of 1.5 m each⁽³⁷⁾. The participants performed two trials with their usual walking paces, and the average rounded to the nearest 0.01 m/s was taken for the analysis. The five-times sit-to-stand test was conducted by measuring the time it took for the participants to stand five times from a sitting position as quickly as possible from a straight-backed armchair without using their arms⁽³⁸⁾. The SPPB consists of the 4-m usual gait speed test measures, five-times sit-to-stand test measures and three standing balance measures⁽³⁸⁾. In the standing balance test, the participants were first asked to stand with their feet placed together as close as possible, then in a semi-tandem position, and finally in a tandem position for 10 s. Each item of the SPPB was scored on a scale of 0–4 based on the normative scores obtained from the Established Population for Epidemiologic Studies of the Elderly, which makes the total possible score between 0 and 12⁽³⁹⁾.

Definitions of sarcopenic obesity. While there is no global consensus to define obesity by the percentage of body fat⁽⁴⁰⁾, the commonly used definition of obesity for older population was suggested in the previous research of New Mexico Aging Process Study. It defined obesity as the percentage of body fat greater than 60th percentile in the study population resulting in cut-off values of $\geq 28\%$ for men and $\geq 40\%$ for women^(5,41). Followed by the standard of the New Mexico Aging Process Study, we defined obesity as a high total fat mass greater than 60th percentile of our study population according to the percentage of body fat. The resulting cut-off values were $\geq 28.2\%$ for men and $\geq 38.8\%$ for women, which correspond to those of the New Mexico Aging Process Study.

Three different definitions of sarcopenia were established based on the Asian Working Group for Sarcopenia 2019 consensus⁽²⁵⁾, which were as follows: (1) low muscle mass, (2) low muscle mass with low muscle strength and/or slow gait speed and (3) low muscle mass with low muscle strength and/or physical performance (slow gait speed, poor performance in the five-times sit-to-stand test and/or low SPPB score). By combining the definitions of obesity and sarcopenia, we established the following three sets of diagnostic criteria for sarcopenic obesity:

Criterion 1: High fat mass + low muscle mass

Criterion 2: High fat mass + low muscle mass + low muscle strength and/or slow gait speed

Criterion 3: High fat mass + low muscle mass + low muscle strength and/or physical performance

Low muscle mass was defined as an ASM/height² value of $< 7.00 \text{ kg/m}^2$ for men and $< 5.40 \text{ kg/m}^2$ for women; low muscle strength was defined as a grip strength of $< 28 \text{ kg}$ for men and $< 18 \text{ kg}$ for women; the cut-off scores for the 4-m usual gait speed, five-times sit-to-stand test and SPPB for low physical performance were $< 1.0 \text{ m/s}$, $\geq 12 \text{ s}$ and ≤ 9 , respectively, for both sexes⁽²⁵⁾.

Statistical analyses

Data are presented as mean \pm standard deviation (SD) for continuous variables and as numbers (percentages) for categorical variables. Continuous variables with skewed distributions are reported as median (interquartile range). To assess the differences in characteristics between the sexes, the means or medians of the two groups were compared using the Student's *t* test or Mann–Whitney *U*-test, respectively. The percentages of categorical variables were compared using the χ^2 or Fisher's exact test, as appropriate. As there was a significant sex-specific difference in the association between the anthropometric indices and sarcopenic obesity in the exploratory data analysis, all the analyses were stratified by sex. The association between the anthropometric indices and sarcopenic obesity was evaluated in the unadjusted and age-adjusted model using binary logistic regression. The results were reported as odds ratio (OR) according to the quartiles of each anthropometric index and corresponding 95% CI to compare the strengths of the associations of the indices measured on different scales. The OR per SD were calculated using a multiple logistic regression model, and the predicted probability calculated from this model was used to evaluate the discriminative ability of the indices for sarcopenic obesity by analysing the receiver operating characteristic curve and the area under the receiver operating characteristic curve (AUC) (95% CI). The AUC of the anthropometric indices were compared using DeLong's method⁽⁴²⁾. The correlation between the anthropometric indices and continuous components of sarcopenic obesity was evaluated using Pearson's or Spearman's correlation analysis, according to the distribution of variables. Statistical significance was set at a $P < 0.05$. All statistical analyses were performed using SAS software (version 9.4; SAS Institute Inc.) and R (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria). This study is a secondary analysis; the sample size was determined by recruitment in the KFACS⁽³⁴⁾ and satisfied the rule of ten events per variable in logistic regression analysis⁽⁴³⁾.

Results

The characteristics of the study participants are listed in Table 1. This study included 1032 men and 999 women. Men were significantly older (76.4 ± 3.9 years *v.* 75.4 ± 3.9 years), had a higher WC (88.4 ± 8.3 cm *v.* 86.0 ± 8.2 cm), a lower BMI (23.9 ± 2.8 *v.* 24.4 ± 2.8), WHtR (0.54 ± 0.05 cm *v.* 0.57 ± 0.05 cm) and WWI (11.0 ± 0.6 cm/ $\sqrt{\text{kg}}$ *v.* 11.5 ± 0.7 cm/ $\sqrt{\text{kg}}$) compared with women. Men were also more likely to have higher incidence rates of myocardial infarction, cerebrovascular disease, diabetes



Table 1. Characteristics of the study participants (Mean values and standard deviations)

| Variables | Total | | Men | | Women | | P |
|---|------------------|------|------------------|------|-----------------|------|---------|
| | Mean (n 2031) | SD | Mean (n 1032) | SD | Mean (n 999) | SD | |
| Age, years | 75.9 | 3.9 | 76.4 | 3.9 | 75.4 | 3.9 | < 0.001 |
| Height, cm | 158.5 | 8.4 | 164.9 | 5.7 | 151.9 | 5.2 | < 0.001 |
| Weight, kg | 60.8 | 9.3 | 65.0 | 8.9 | 56.5 | 7.7 | < 0.001 |
| BMI, kg/m ² | 24.1 | 2.8 | 23.9 | 2.8 | 24.4 | 2.8 | < 0.001 |
| WC, cm | 87.2 | 8.3 | 88.4 | 8.3 | 86.0 | 8.2 | < 0.001 |
| WHtR, cm | 0.55 | 0.05 | 0.54 | 0.05 | 0.57 | 0.05 | < 0.001 |
| WWI, cm/ $\sqrt{\text{kg}}$ | 11.2 | 0.7 | 11.0 | 0.6 | 11.5 | 0.7 | < 0.001 |
| Percentage of body fat | 31.5 | 7.9 | 26.3 | 6.0 | 36.8 | 5.9 | < 0.001 |
| SBP, mmHg | 131.1 | 15.6 | 131.1 | 15.3 | 131.1 | 15.9 | 0.962 |
| DBP, mmHg | 77.4 | 9.1 | 78.0 | 9.1 | 76.9 | 9.2 | 0.009 |
| | <i>n</i> | % | <i>n</i> | % | <i>n</i> | % | |
| Comorbidity | | | | | | | |
| Hypertension | 1122 | 55.3 | 546 | 53.0 | 576 | 57.7 | 0.033 |
| Dyslipidaemia | 654 | 32.6 | 249 | 24.4 | 405 | 41.2 | < 0.001 |
| Myocardial infarction | 51 | 2.5 | 39 | 3.8 | 12 | 1.2 | < 0.001 |
| Heart failure | 11 | 0.6 | 6 | 0.6 | 5 | 0.5 | 0.822 |
| Angina | 113 | 5.6 | 62 | 6.0 | 51 | 5.2 | 0.399 |
| Peripheral artery disease | 17 | 0.8 | 11 | 1.1 | 6 | 0.6 | 0.258 |
| CVD | 89 | 4.4 | 60 | 5.8 | 29 | 2.9 | 0.001 |
| Diabetes mellitus | 432 | 21.3 | 244 | 23.7 | 188 | 18.9 | 0.008 |
| Osteoarthritis | 384 | 19.0 | 106 | 10.3 | 278 | 28.0 | < 0.001 |
| Rheumatoid arthritis | 38 | 1.9 | 8 | 0.8 | 30 | 3.0 | < 0.001 |
| Osteoporosis | 259 | 12.9 | 26 | 2.5 | 233 | 23.8 | < 0.001 |
| Asthma | 65 | 3.2 | 25 | 2.4 | 40 | 4.0 | 0.043 |
| COPD | 23 | 1.1 | 20 | 1.9 | 3 | 0.3 | 0.001 |
| | Mean | SD | Mean | SD | Mean | SD | |
| Laboratory results | | | | | | | |
| Creatinine, mg/dl | 0.85 | 0.28 | 0.98 | 0.30 | 0.72 | 0.16 | < 0.001 |
| eGFR, ml/min/1.73 m ² | 81.2 | 19.0 | 79.0 | 19.3 | 83.4 | 18.6 | < 0.001 |
| FBS | | | | | | | |
| Median | 97 | | 99 | | 96 | | < 0.001 |
| IQR | 90–110 | | 91–112 | | 89–108 | | |
| Total cholesterol, mg/dl | 175.2 | 35.7 | 168.6 | 34.7 | 182.1 | 35.5 | < 0.001 |
| Triglyceride | | | | | | | |
| Median | 105 | | 100 | | 110 | | < 0.001 |
| IQR | 79–142 | | 75–137 | | 83–146 | | |
| HDL-cholesterol, mg/dl | 53.0 | 14.2 | 50.8 | 14.3 | 55.2 | 13.8 | < 0.001 |
| LDL-cholesterol, mg/dl | 108.9 | 33.0 | 104.5 | 31.7 | 113.4 | 33.9 | < 0.001 |
| HbA1c, % | 6.0 | 0.8 | 6.0 | 0.8 | 6.0 | 0.8 | 0.158 |
| Skeletal muscle mass | | | | | | | |
| ASM by DXA, kg | 16.4 | 3.7 | 19.2 | 2.7 | 13.5 | 1.8 | < 0.001 |
| ASM/height ² , kg/m ² | 6.4 | 1.0 | 7.0 | 0.8 | 5.8 | 0.7 | < 0.001 |
| Low muscle mass | | | | | | | |
| <i>n</i> | 769 | | 498 | | 271 | | < 0.001 |
| % | 37.9 | | 48.3 | | 27.1 | | |
| Maximum grip strength, kg | 27.0 | 7.4 | 32.5 | 5.7 | 21.3 | 3.9 | < 0.001 |
| Low muscle strength | | | | | | | |
| <i>n</i> | 414 | | 224 | | 190 | | 0.133 |
| % | 20.4 | | 21.7 | | 19.0 | | |
| Physical performance | | | | | | | |
| 4-m usual gait speed, m/s | 1.1 | 0.3 | 1.2 | 0.3 | 1.1 | 0.2 | < 0.001 |
| | <i>n</i> | % | <i>n</i> | % | <i>n</i> | % | |
| 4-m usual gait speed < 1.0 m/s | 571 | 28.1 | 240 | 23.3 | 331 | 33.1 | < 0.001 |
| Five-times sit-to-stand test | | | | | | | |
| Median | 10.5 | | 10.0 | | 11.2 | | < 0.001 |
| IQR | 8.7–12.9 | | 8.4–12.3 | | 9.2–13.7 | | |
| Five-times sit-to-stand test \geq 12 s | 688 | 33.9 | 287 | 27.8 | 401 | 40.1 | < 0.001 |

Table 1. (Continued)

| | <i>n</i> | % | <i>n</i> | % | <i>n</i> | % | |
|--------------------------|----------|------|----------|------|----------|------|---------|
| SPPB score, median (IQR) | | | | | | | |
| Median | | | | | | | < 0.001 |
| IQR | 11 | | 12 | | 11 | | |
| | 10–12 | | 11–12 | | 10–12 | | |
| SPPB score ≤ 9 points | 294 | 14.5 | 102 | 9.9 | 192 | 19.2 | < 0.001 |
| Low physical performance | 946 | 46.6 | 408 | 39.5 | 538 | 53.9 | < 0.001 |
| Sarcopenic obesity | | | | | | | |
| Criterion 1 | 368 | 18.1 | 225 | 21.8 | 143 | 14.3 | < 0.001 |
| Criterion 2 | 178 | 8.8 | 108 | 10.5 | 70 | 7.0 | 0.006 |
| Criterion 3 | 234 | 11.5 | 131 | 12.7 | 103 | 10.3 | 0.093 |

WC, waist circumference; WHtR, waist-to-height ratio; WWI, weight-adjusted waist index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, cardiovascular diseases; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; FBS, fetal bovine serum; ASM, appendicular skeletal muscle mass; DXA, dual-energy X-ray absorptiometry; SPPB, short physical performance battery; IQR, interquartile range.

Criterion 1: high-fat mass + low muscle mass; Criterion 2: high-fat mass + low muscle mass + low muscle strength and/or slow gait speed and Criterion 3: high-fat mass + low muscle mass + low muscle strength and/or low physical performance.

High-fat mass: body fat percentage of ≥ 28.2% for men and ≥ 38.8% for women; low muscle mass: ASM/height² of < 7.00 kg/m² for men and < 5.40 kg/m² for women; low muscle strength: grip strength of < 28 kg for men and < 18 kg for women; slow gait speed: 4-m usual gait speed of < 1.0 m/s and low physical performance: five-times sit-to-stand test score of ≥ 12 s, 4-m usual gait speed of < 1.0 m/s and/or SPPB score of ≤ 9.

Variables are expressed as means ± standard deviation for continuous variables and as *n* (%) for categorical variables. Continuous variables with skewed distributions were reported as median (IQR). *P* values were obtained using the χ^2 test, Fisher's exact test or Student's *t* test, as appropriate.

mellitus and chronic obstructive pulmonary disease than women. On the other hand, women were more likely to have higher incidence rates of hypertension, dyslipidaemia, osteoarthritis, rheumatoid arthritis, osteoporosis and asthma than men. The prevalence of sarcopenic obesity was higher in men than in women according to criteria 1 (21.8% *v.* 14.3%), 2 (10.5% *v.* 7.0%) and 3 (12.7% *v.* 10.3%); the difference between men and women was not significant in criteria 3 (*P* = 0.093). The percentage of body fat was lower in men than in women (26.3 ± 6.0% *v.* 36.8 ± 5.9%). Although men had higher ASM (19.2 ± 2.7 kg *v.* 13.5 ± 1.8 kg) and ASM/height² (7.0 ± 0.8 kg/m² *v.* 5.8 ± 0.7 kg/m²) than women, the proportion of low muscle mass was also higher in men than in women (48.3% *v.* 27.1%). The difference between the sexes in the proportion of low muscle strength was not significant (21.7% in men and 19.0% in women, *P* = 0.133). The proportion of slow gait speed (23.3% *v.* 33.1%) and low physical performance (39.5% *v.* 53.9%) was lower in men than in women.

Association between anthropometric indices and sarcopenic obesity

The age-adjusted prevalence of sarcopenic obesity was high in men with higher WWI and WHtR for all the three diagnostic criteria, but not in women with higher WWI and WHtR (Fig. 1). Followed by the result, we analysed the age-adjusted OR of sarcopenic obesity according to the quartiles of the anthropometric indices as illustrated in Table 2. In men, higher WWI and WHtR quartiles were associated with higher risk of sarcopenic obesity for all the three diagnostic criteria, with the OR being the highest in the fourth quartiles of the WWI (OR: 5.84, 95% CI: 3.51, 9.70, *P*_{for trend} < 0.001 in criterion 1; OR: 14.64, 95% CI: 5.20, 41.25 in criterion 2, *P*_{for trend} < 0.001; and OR: 10.99, 95% CI: 4.92, 24.85, *P*_{for trend} < 0.001 in criterion 3) and WHtR (OR: 3.94, 95% CI: 2.41, 6.45, *P*_{for trend} < 0.001 in criterion 1; OR: 5.73, 95% CI: 2.72–12.05, *P*_{for trend} < 0.001 in criterion 2; and OR: 5.99, 95% CI: 3.05, 11.79, *P*_{for trend} < 0.001 in criterion 3). The OR of sarcopenic obesity were higher in the fourth quartiles of the WWI than in

those of the WHtR, especially based on criteria 2 and 3, which included muscle strength and/or physical performance as diagnostic components of sarcopenic obesity. WC also showed the highest OR in the fourth quartiles on criteria 2 (OR: 3.61, 95% CI: 1.86, 7.01, *P*_{for trend} < 0.001) and 3 (OR: 4.32, 95% CI: 2.31, 8.10, *P*_{for trend} < 0.001), but their values were lower compared with WWI and WHtR. Meanwhile, no anthropometric indices were significantly associated with sarcopenic obesity in women. Similar results were observed in the unadjusted model in both men and women (online Supplementary Table S1).

We also analysed the association of the anthropometric indices with sarcopenic obesity by OR per SD increase (online Supplementary Table S2). The highest OR were identified in WWI in men, whereas no anthropometric indices were significantly associated with sarcopenic obesity in women. We observed an independent association between the anthropometric indices and sarcopenia and obesity (online Supplementary Table S3) and found that WWI was the only index that was positively correlated with sarcopenia in men; thus, the coexistence of sarcopenia and obesity led to an increased association with WWI. However, this association was not observed in women due to the lack of a correlation between WWI and sarcopenia.

The discriminative ability of the anthropometric indices for predicting sarcopenic obesity

The discriminative ability of the anthropometric indices for predicting sarcopenic obesity was determined using the age-adjusted receiver operating characteristic curves for men and women (Fig. 2), and the AUC of the anthropometric indices for the diagnosis of sarcopenic obesity were obtained (online Supplementary Table S4). Although the values were relatively modest, the highest AUC were observed for the WWI (AUC: 0.692, 95% CI: 0.653, 0.731 in criterion 1; AUC: 0.799, 95% CI: 0.755, 0.842 in criterion 2 and AUC: 0.781, 95% CI: 0.738, 0.824 in criterion 3) in men; the WWI had the best diagnostic power for sarcopenic obesity followed by WHtR, WC and BMI




Fig. 1. Age-adjusted prevalence of sarcopenic obesity according to the quartiles of the anthropometric indices. WWI, weight-adjusted waist index; WC, waist circumference; WHtR, waist-to-height ratio. Criterion 1: high fat mass + low muscle mass; Criterion 2: high fat mass + low muscle mass + low muscle strength and/or slow gait speed; Criterion 3: high fat mass + low muscle mass + low muscle strength and/or low physical performance. High fat mass: body fat percentage of $\geq 28.2\%$ for men and $\geq 38.8\%$ for women; low muscle mass: appendicular skeletal muscle mass/height² of $< 7.00 \text{ kg/m}^2$ for men and $< 5.40 \text{ kg/m}^2$ for women; low muscle strength: grip strength of $< 28 \text{ kg}$ for men and $< 18 \text{ kg}$ for women; slow gait speed: 4-m usual gait speed of $< 1.0 \text{ m/s}$ and low physical performance: five-times sit-to-stand test score of $\geq 12 \text{ s}$, 4-m usual gait speed of $< 1.0 \text{ m/s}$ and/or short physical performance battery score of ≤ 9 .

Table 2. Age-adjusted odds ratios of sarcopenic obesity according to the quartiles of the anthropometric indices (Odd ratio and 95 % confidence intervals)

| Quartile group | Range | Criterion 1 | | | | | | Criterion 2 | | | | | | Criterion 3 | | | | | |
|-------------------------------------|------------|-------------|------|-----------------|------------|---------|----|-------------|-----------------|-------------|---------|----|------|-----------------|-------------|---------|--|--|--|
| | | n | % | Age-adjusted OR | 95 % CI | P | n | % | Age-adjusted OR | 95 % CI | P | n | % | Age-adjusted OR | 95 % CI | P | | | |
| WWI | | | | | | | | | | | | | | | | | | | |
| Men | | | | | | | | | | | | | | | | | | | |
| 1st | 9.1–10.6 | 22 | 8.5 | 1 (Reference) | | | 4 | 1.6 | 1 (Reference) | | | 7 | 2.7 | 1 (Reference) | | | | | |
| 2nd | 10.6–11.0 | 45 | 17.4 | 2.25 | 1.31, 3.88 | 0.003 | 15 | 5.8 | 3.83 | 1.25, 11.76 | 0.019 | 19 | 7.4 | 2.80 | 1.16, 6.81 | 0.023 | | | |
| 3rd | 11.0–11.4 | 63 | 24.4 | 3.34 | 1.98, 5.63 | < 0.001 | 32 | 12.4 | 8.10 | 2.81, 23.35 | < 0.001 | 37 | 14.3 | 5.53 | 2.41, 12.70 | < 0.001 | | | |
| 4th | 11.4–12.9 | 95 | 36.8 | 5.84 | 3.51, 9.70 | < 0.001 | 57 | 22.1 | 14.64 | 5.20, 41.25 | < 0.001 | 68 | 26.4 | 10.99 | 4.92, 24.85 | < 0.001 | | | |
| <i>P</i> _{for trend} | | | | | | < 0.001 | | | | | < 0.001 | | | | | < 0.001 | | | |
| Women | | | | | | | | | | | | | | | | | | | |
| 1st | 9.5–10.9 | 35 | 14.1 | 1 (Reference) | | | 19 | 7.6 | 1 (Reference) | | | 26 | 10.4 | 1 (Reference) | | | | | |
| 2nd | 10.6–11.5 | 34 | 13.6 | 0.95 | 0.57, 1.57 | 0.830 | 11 | 4.4 | 0.53 | 0.24, 1.14 | 0.103 | 18 | 7.2 | 0.64 | 0.34, 1.20 | 0.163 | | | |
| 3rd | 11.5–11.9 | 37 | 14.8 | 1.03 | 0.62, 1.69 | 0.922 | 17 | 6.8 | 0.78 | 0.39, 1.55 | 0.482 | 28 | 11.2 | 0.99 | 0.56, 1.76 | 0.980 | | | |
| 4th | 11.9–14.0 | 37 | 14.8 | 0.95 | 0.57, 1.58 | 0.849 | 23 | 9.2 | 0.86 | 0.45, 1.65 | 0.656 | 31 | 12.4 | 0.94 | 0.53, 1.65 | 0.820 | | | |
| <i>P</i> _{for trend} | | | | | | 0.938 | | | | | 0.955 | | | | | 0.811 | | | |
| <i>P</i> _{for interaction} | | | | | | < 0.001 | | | | | < 0.001 | | | | | < 0.001 | | | |
| BMI | | | | | | | | | | | | | | | | | | | |
| Men | | | | | | | | | | | | | | | | | | | |
| 1st | 14.5–22.0 | 28 | 10.9 | 1 (Reference) | | | 17 | 6.6 | 1 (Reference) | | | 18 | 7.0 | 1 (Reference) | | | | | |
| 2nd | 22.0–23.9 | 74 | 28.7 | 3.49 | 2.16, 5.63 | < 0.001 | 31 | 12.0 | 2.17 | 1.16, 4.07 | 0.016 | 39 | 15.1 | 2.61 | 1.44, 4.73 | 0.002 | | | |
| 3rd | 23.9–25.7 | 76 | 29.5 | 3.61 | 2.24, 5.83 | < 0.001 | 32 | 12.4 | 2.26 | 1.21, 4.22 | 0.011 | 41 | 15.9 | 2.77 | 1.54, 5.01 | < 0.001 | | | |
| 4th | 25.7–33.1 | 47 | 18.2 | 1.94 | 1.17, 3.21 | 0.011 | 28 | 10.9 | 1.99 | 1.05, 3.77 | 0.035 | 33 | 12.8 | 2.19 | 1.19, 4.03 | 0.012 | | | |
| <i>P</i> _{for trend} | | | | | | 0.029 | | | | | 0.050 | | | | | 0.021 | | | |
| Women | | | | | | | | | | | | | | | | | | | |
| 1st | 16.0–22.6 | 24 | 9.6 | 1 (Reference) | | | 13 | 5.2 | 1 (Reference) | | | 19 | 7.6 | 1 (Reference) | | | | | |
| 2nd | 22.6–24.4 | 52 | 20.8 | 2.56 | 1.52, 4.32 | < 0.001 | 21 | 8.4 | 1.87 | 0.90, 3.87 | 0.091 | 33 | 13.2 | 2.01 | 1.10, 3.67 | 0.023 | | | |
| 3rd | 24.4–26.2 | 48 | 19.2 | 2.33 | 1.37, 3.94 | 0.002 | 24 | 9.6 | 2.24 | 1.10, 4.57 | 0.026 | 36 | 14.4 | 2.27 | 1.25, 4.11 | 0.007 | | | |
| 4th | 26.2–33.2 | 19 | 7.6 | 0.79 | 0.42, 1.48 | 0.456 | 12 | 4.8 | 0.96 | 0.43, 2.18 | 0.931 | 15 | 6.0 | 0.80 | 0.40, 1.63 | 0.539 | | | |
| <i>P</i> _{for trend} | | | | | | 0.477 | | | | | 0.877 | | | | | 0.769 | | | |
| <i>P</i> _{for interaction} | | | | | | 0.166 | | | | | 0.417 | | | | | 0.141 | | | |
| WC | | | | | | | | | | | | | | | | | | | |
| Men | | | | | | | | | | | | | | | | | | | |
| 1st | 60.0–83.0 | 23 | 8.9 | 1 (Reference) | | | 13 | 5.0 | 1 (Reference) | | | 14 | 5.4 | 1 (Reference) | | | | | |
| 2nd | 83.1–88.5 | 57 | 22.1 | 2.99 | 1.77, 5.03 | < 0.001 | 21 | 8.1 | 1.82 | 0.88, 3.75 | 0.105 | 25 | 9.7 | 1.99 | 1.01, 3.95 | 0.048 | | | |
| 3rd | 88.6–93.9 | 75 | 29.1 | 4.33 | 2.61, 7.19 | < 0.001 | 35 | 13.6 | 3.23 | 1.65, 6.32 | < 0.001 | 43 | 16.7 | 3.73 | 1.97, 7.05 | < 0.001 | | | |
| 4th | 94.0–115.0 | 70 | 27.1 | 3.91 | 2.34, 6.51 | < 0.001 | 39 | 15.1 | 3.61 | 1.86, 7.01 | < 0.001 | 49 | 19.0 | 4.32 | 2.31, 8.10 | < 0.001 | | | |
| <i>P</i> _{for trend} | | | | | | < 0.001 | | | | | < 0.001 | | | | | < 0.001 | | | |
| Women | | | | | | | | | | | | | | | | | | | |
| 1st | 59.5–80.0 | 32 | 12.9 | 1 (Reference) | | | 18 | 7.2 | 1 (Reference) | | | 23 | 9.2 | 1 (Reference) | | | | | |
| 2nd | 80.1–86.0 | 42 | 16.8 | 1.41 | 0.85, 2.32 | 0.180 | 17 | 6.8 | 0.99 | 0.49, 1.99 | 0.975 | 25 | 10.0 | 1.14 | 0.63, 2.09 | 0.665 | | | |
| 3rd | 86.1–91.5 | 40 | 16.0 | 1.30 | 0.78, 2.14 | 0.313 | 20 | 8.0 | 1.14 | 0.58, 2.23 | 0.702 | 31 | 12.4 | 1.41 | 0.79, 2.52 | 0.239 | | | |
| 4th | 91.6–111.6 | 29 | 11.6 | 0.88 | 0.51, 1.51 | 0.642 | 15 | 6.0 | 0.77 | 0.38, 1.58 | 0.478 | 24 | 9.6 | 1.00 | 0.55, 1.84 | 0.995 | | | |
| <i>P</i> _{for trend} | | | | | | 0.605 | | | | | 0.598 | | | | | 0.811 | | | |
| <i>P</i> _{for interaction} | | | | | | 0.001 | | | | | 0.015 | | | | | 0.007 | | | |
| WHtR | | | | | | | | | | | | | | | | | | | |
| Men | | | | | | | | | | | | | | | | | | | |
| 1st | 0.35–0.51 | 25 | 9.7 | 1 (Reference) | | | 9 | 3.5 | 1 (Reference) | | | 11 | 4.3 | 1 (Reference) | | | | | |
| 2nd | 0.51–0.54 | 54 | 20.9 | 2.52 | 1.51, 4.21 | < 0.001 | 21 | 8.1 | 2.59 | 1.16, 5.82 | 0.021 | 25 | 9.7 | 2.52 | 1.21, 5.26 | 0.014 | | | |
| 3rd | 0.54–0.57 | 68 | 26.4 | 3.32 | 2.02, 5.47 | < 0.001 | 32 | 12.4 | 3.91 | 1.81, 8.43 | < 0.001 | 39 | 15.1 | 3.99 | 1.98, 8.01 | < 0.001 | | | |

Anthropometric indices for sarcopenic obesity



Table 2. (Continued)

| Quartile group | Range | Criterion 1 | | | Criterion 2 | | | Criterion 3 | | | | | | | | |
|-------------------------------------|-----------|-------------|------|-----------------|-------------|---------|----|-------------|-----------------|-------------|---------|----|------|---------------|-------------|---------|
| | | n | % | Age-adjusted OR | 95% CI | P | n | % | Age-adjusted OR | 95% CI | P | | | | | |
| 4th | 0.57–0.72 | 78 | 30.2 | 3.94 | 2.41, 6.45 | < 0.001 | 46 | 17.8 | 5.73 | 2.72, 12.05 | < 0.001 | 56 | 21.7 | 5.99 | 3.05, 11.79 | < 0.001 |
| <i>P</i> _{for trend} | | | | | | < 0.001 | | | | | < 0.001 | | | | | < 0.001 |
| Women | | | | | | | | | | | | | | | | |
| 1st | 0.41–0.53 | 29 | 11.6 | 1 (Reference) | | | 16 | 6.4 | 1 (Reference) | | | 22 | 8.8 | 1 (Reference) | | |
| 2nd | 0.53–0.57 | 42 | 16.8 | 1.53 | 0.92, 2.55 | 0.102 | 15 | 6.0 | 0.94 | 0.45, 1.96 | 0.866 | 25 | 10.0 | 1.15 | 0.63, 2.12 | 0.647 |
| 3rd | 0.57–0.60 | 42 | 16.8 | 1.51 | 0.90, 2.51 | 0.116 | 19 | 7.6 | 1.15 | 0.57, 2.32 | 0.692 | 31 | 12.4 | 1.42 | 0.79, 2.54 | 0.239 |
| 4th | 0.60–0.76 | 30 | 12.0 | 0.95 | 0.55, 1.64 | 0.847 | 20 | 8.0 | 1.01 | 0.51, 2.02 | 0.974 | 25 | 10.0 | 0.96 | 0.52, 1.77 | 0.897 |
| <i>P</i> _{for trend} | | | | | | 0.823 | | | | | 0.843 | | | | | 0.943 |
| <i>P</i> _{for interaction} | | | | | | 0.001 | | | | | 0.010 | | | | | 0.001 |

WWI, weight-adjusted waist index; WC, waist circumference; WHtR, waist-to-height ratio. Criterion 1: high fat mass + low muscle mass; Criterion 2: high fat mass + low muscle mass + low muscle strength and/or slow gait speed and Criterion 3: high fat mass + low muscle mass + low muscle strength and/or low physical performance. High fat mass: body fat percentage of $\geq 28.2\%$ for men and $\geq 38.8\%$ for women; low muscle mass: appendicular skeletal muscle mass/height² of $< 7.00 \text{ kg/m}^2$ for men and $< 5.40 \text{ kg/m}^2$ for women; low muscle strength: grip strength of $< 28 \text{ kg}$ for men and $< 18 \text{ kg}$ for women; slow gait speed: 4-m usual gait speed of $< 1.0 \text{ m/s}$ and low physical performance: five-times sit-to-stand test score of $\geq 12 \text{ s}$, 4-m usual gait speed of $< 1.0 \text{ m/s}$ and/or short physical performance battery score of ≤ 9 . P values were obtained using a binary logistic regression model.

according to all the criteria (all *P*_{for difference} in AUC < 0.05). In women, the diagnostic power of anthropometric indices could not be determined because the difference between the AUC of anthropometric indices was not significant according to all the criteria. We obtained similar results for both men and women in the unadjusted model (online Supplementary Fig. S1 and Supplementary Table S5).

The optimal cut-off values, sensitivity and specificity of the anthropometric indices for the diagnosis of sarcopenic obesity in men were also reported, according to Youden's index (online Supplementary Table S6).

Correlation between the anthropometric indices and components of sarcopenic obesity

The correlation between the anthropometric indices and each diagnostic component of sarcopenic obesity is shown in Table 3. All anthropometric indices were positively correlated with the percentage of body fat in both men and women. WC showed the strongest correlation ($r = 0.695, P < 0.001$) in men followed by WHtR ($r = 0.689, P < 0.001$), BMI ($r = 0.652, P < 0.001$) and WWI ($r = 0.480, P < 0.001$). In women, BMI showed the strongest correlation with the percentage of body fat ($r = 0.662, P < 0.001$) followed by WC ($r = 0.542, P < 0.001$), WHtR ($r = 0.499, P < 0.001$) and WWI ($r = 0.146, P < 0.001$). WWI had the lowest correlation coefficient for percentage of body fat in both men and women. However, WWI was the only index that showed a negative correlation with ASM/height² ($r = -0.073, P = 0.020$) in men, which confirmed that the WWI discriminated muscle mass from fat mass. Other indices did not discriminate muscle mass from fat mass in men; BMI ($r = 0.602, P < 0.001$), WC ($r = 0.351, P < 0.001$) and WHtR ($r = 0.339, P < 0.001$) all showed positive correlation with ASM/height². In women, all the anthropometric indices did not discriminate muscle mass from fat mass; they all showed positive correlation with ASM/height² (BMI ($r = 0.483, P < 0.001$); WC ($r = 0.348, P < 0.001$); WHtR ($r = 0.358, P < 0.001$) and WWI ($r = 0.102, P = 0.001$)).

The overall correlations between anthropometric indices and physical function measurements were weak; yet, WWI was the only index that showed a significant inverse relationship with physical function measurements in both men and women. Higher WWI was associated with lower maximum grip strength ($r = -0.245, P < 0.001$ in men; $r = -0.215, P < 0.001$ in women), 4-m usual gait speed ($r = -0.165, P < 0.001$ in men; $r = -0.213, P < 0.001$ in women) and SPPB score ($r = -0.138, P < 0.001$ in men; $r = -0.166, P < 0.001$ in women) and a longer time for the five-times sit-to-stand test ($r = 0.178, P < 0.001$ in men; $r = 0.131, P < 0.001$ in women). Such consistency was not observed in BMI and WC. WHtR showed inverse relationship with physical function measurements, similar to WWI; however, in men, the correlations of WHtR with maximum grip strength ($r = -0.026, P = 0.411$) and SPPB score ($r = -0.048, P = 0.124$) were not statistically significant.

Discussion

This is the first study that analysed the association of different anthropometric indices, including BMI, WC, WHtR and WWI,




Fig. 2. Age-adjusted ROC curves for sarcopenic obesity according to the anthropometric indices. ROC, receiver operating characteristic; WWI, weight-adjusted waist index; WC, waist circumference; WHtR, waist-to-height ratio. Criterion 1: high-fat mass + low muscle mass; Criterion 2: high-fat mass + low muscle mass + low muscle strength and/or slow gait speed; Criterion 3: high-fat mass + low muscle mass + low muscle strength and/or low physical performance. High-fat mass: body fat percentage of $\geq 28.2\%$ for men and $\geq 38.8\%$ for women; low muscle mass: appendicular skeletal muscle mass/height² of < 7.00 kg/m² for men and < 5.40 kg/m² for women; low muscle strength: grip strength of < 28 kg for men and < 18 kg for women; slow gait speed: 4-m usual gait speed of < 1.0 m/s and low physical performance: five-times sit-to-stand test score of ≥ 12 s, 4-m usual gait speed of < 1.0 m/s and/or short physical performance battery score of ≤ 9 .

Table 3. Correlation between the anthropometric indices and diagnostic components of sarcopenic obesity (Coefficients and 95 % confidence intervals)

| | WWI | | | BMI | | | WC | | | WHtR | | |
|-------------------------------|--------|----------------|---------|--------|----------------|---------|--------|----------------|---------|--------|----------------|---------|
| | r | 95 % CI | P | r | 95 % CI | P | r | 95 % CI | P | r | 95 % CI | P |
| Men n 1032 | | | | | | | | | | | | |
| Percentage of body fat* | 0.480 | 0.431, 0.526 | < 0.001 | 0.652 | 0.616, 0.686 | < 0.001 | 0.695 | 0.662, 0.725 | < 0.001 | 0.689 | 0.656, 0.720 | < 0.001 |
| ASM/height ² | -0.073 | -0.133, -0.012 | 0.020 | 0.602 | 0.562, 0.639 | < 0.001 | 0.351 | 0.297, 0.404 | < 0.001 | 0.339 | 0.284, 0.392 | < 0.001 |
| Maximum grip strength* | -0.245 | -0.302, -0.187 | < 0.001 | 0.182 | 0.123, 0.241 | < 0.001 | 0.105 | 0.044, 0.165 | 0.001 | -0.026 | -0.086, 0.035 | 0.411 |
| 4-m usual gait speed* | -0.165 | -0.224, -0.105 | < 0.001 | -0.009 | -0.070, 0.052 | 0.773 | -0.058 | -0.119, 0.003 | 0.061 | -0.101 | -0.161, -0.040 | 0.001 |
| Five-times-sit-to-stand test† | 0.178 | 0.118, 0.236 | < 0.001 | -0.031 | -0.092, 0.030 | 0.322 | 0.076 | 0.015, 0.136 | 0.015 | 0.097 | 0.036, 0.157 | 0.002 |
| SPPB score† | -0.138 | -0.197, -0.077 | < 0.001 | 0.077 | 0.016, 0.137 | 0.014 | -0.027 | -0.088, 0.034 | 0.392 | -0.048 | -0.109, 0.013 | 0.124 |
| Women n 999 | | | | | | | | | | | | |
| Percentage of body fat* | 0.146 | 0.085, 0.206 | < 0.001 | 0.662 | 0.626, 0.696 | < 0.001 | 0.542 | 0.497, 0.585 | < 0.001 | 0.499 | 0.451, 0.544 | < 0.001 |
| ASM/height ² | 0.102 | 0.041, 0.163 | 0.001 | 0.483 | 0.434, 0.529 | < 0.001 | 0.348 | 0.292, 0.401 | < 0.001 | 0.358 | 0.303, 0.411 | < 0.001 |
| Maximum grip strength* | -0.214 | -0.272, -0.154 | < 0.001 | 0.070 | 0.008, 0.131 | 0.028 | 0.036 | -0.027, 0.097 | 0.262 | -0.096 | -0.157, -0.034 | 0.002 |
| 4-m usual gait speed* | -0.213 | -0.272, -0.153 | < 0.001 | -0.076 | -0.137, -0.014 | 0.016 | -0.111 | -0.172, -0.049 | < 0.001 | -0.184 | -0.243, -0.123 | < 0.001 |
| Five-times-sit-to-stand test† | 0.131 | 0.070, 0.192 | < 0.001 | 0.108 | 0.050, 0.169 | 0.001 | 0.164 | 0.103, 0.223 | < 0.001 | 0.155 | 0.094, 0.215 | < 0.001 |
| SPPB score† | -0.166 | -0.225, -0.105 | < 0.001 | -0.084 | -0.145, -0.022 | 0.008 | -0.148 | -0.209, -0.087 | < 0.001 | -0.158 | -0.218, -0.097 | < 0.001 |

WWI, weight-adjusted waist index; WC, waist circumference; WHtR, waist-to-height ratio; ASM, appendicular skeletal muscle mass; SPPB, short physical performance battery.

* Pearson's correlation coefficient.

† Spearman's correlation coefficient.

with sarcopenic obesity to test their feasibility as screening tool for sarcopenic obesity. In this study, WWI showed the strongest association with sarcopenic obesity in men and was the best screening tool compared with WHtR, WC and BMI. There was no statistical significance between all four anthropometric indices and sarcopenic obesity in women. Our findings also reported that WWI was the only index that discriminated muscle mass and fat mass in men, while all the anthropometric indices did not in women. Furthermore, WWI was the only index that showed significant inverse association with physical function in both men and women. Taken altogether, WWI has potential to be a simple screening tool for sarcopenic obesity in older men.

In our study, BMI reported similar positive correlations with fat mass and muscle mass in both sexes; we confirmed that BMI's inability to discriminate fat mass and muscle mass makes it inappropriate to screen sarcopenic obesity. WC is a measure of abdominal obesity that is highly associated with visceral fat^(44,45). Although WC showed better association with sarcopenic obesity along with reduced positive correlation with muscle mass compared with BMI, it was still too far to say that WC discriminated muscle mass and fat mass. Nevertheless, BMI and WC were good obesity indicators in line with the previous studies^(46,47); WC reported the best correlation with body fat mass in men, while BMI was the best in women. Therefore, we confirmed that BMI and WC cannot solely be used for screening sarcopenic obesity; instead, they have to be combined with physical function indicators^(48,49), which may also reflect low muscle mass. WHtR showed significantly better performance as an indicator of sarcopenic obesity in men compared with BMI and WC possibly due its better reflection of body fat distribution by standardising WC for height. However, it was not free from the influence of WC and similar limitations were observed; it still did not discriminate muscle mass and fat mass and was weakly correlated with physical function measurements, especially with muscle strength. Considering the significant association of WHtR and sarcopenic obesity based on all the three criteria in men, WHtR can be a useful indicator in men when combined with appropriate muscle strength indicator, such as grip strength.

In 2021, the WWI was suggested as an indicator that can reflect high fat mass and low muscle mass simultaneously, although the association of WWI with muscle strength and physical performance was not identified⁽²⁴⁾. Unlike WHtR, WWI standardised WC for weight only and differentiated the effect of height on the same waist⁽²³⁾. In our study, WWI showed a relatively lower correlation with body fat mass compared with the other anthropometric indices for both sexes. However, in men, WWI reflected fat mass and muscle mass in the opposite direction and showed a significant inverse association with physical function. It was the only index that showed a significant positive association with sarcopenia defined as low muscle mass combined with low muscle strength and/or physical performance in men. Consequently, the coexistence of sarcopenia and obesity reported an increased association with the WWI, making it the best index to screen sarcopenic obesity in men compared with the other anthropometric indices. The overall correlations of WWI with muscle mass and each physical function measurement were not strong; still, it was the only index that reflected the

components simultaneously while maintaining statistical significance, which led to a better association between WWI and sarcopenic obesity in men compared with the other indices. Meanwhile, WWI did not reflect muscle mass and fat mass in the opposite direction in women as it did in men; it showed the lowest correlation with fat mass compared with the other indices. As a result, WWI was not significantly associated with sarcopenic obesity in women even it showed a significant inverse association with physical function.

The significant sex-specific difference was observed in WWI, WC and WHtR in the association with sarcopenic obesity. Previous studies have shown that men have significantly higher visceral fat and lower extremity fat than women^(50,51), while women have higher subcutaneous fat and greater fat infiltration into lower extremity muscles than men^(52,53). The sex-specific difference of WWI, WC and WHtR may be attributed to the insufficient reflection of subcutaneous or intermuscular fat. In the previous Health, Aging, and Body Composition Study, a higher amount of subcutaneous fat in women's lower extremity area was independently associated with slow gait speed⁽⁵⁴⁾. We found similar sex-specific difference in mean gait speed in our study population as the proportion of slow gait speed was higher in women. This finding may reflect a higher amount of subcutaneous fat deposited in lower extremity in our women population. In the most recent Multi-Ethnic Study of Atherosclerosis that examined the association between WWI and abdominal fat and muscle mass by CT scans, WWI was not only positively correlated with visceral fat area but also with subcutaneous fat of abdominal area, while negatively correlated with abdominal muscle area⁽⁵⁵⁾. Overall, previous findings suggest WC-driven anthropometric indices may not well reflect lower extremity fat that could have interrupted reciprocal assessment of percentage of body fat and ASM/height² in older women in our study. We were not able to confirm this assumption due to the lack of relevant data; further research into the sex-specific differences is needed, especially regarding relationship between the anthropometric indices and distribution of body fat. In addition, a previous study of Korean community-dwelling older adults found that ASM/height² was the most reliable index for sarcopenia in men in terms of predicting functional limitation, while ASM/weight was better in women⁽⁵⁶⁾. In light of this, we may need a different approach; applying different muscle indices in our study population could have yielded different results. Although we applied ASM/height² in our study according to the Asian Working Group for Sarcopenia 2019 consensus, studies regarding the application of ASM/weight would be intriguing, and further studies on an anthropometric index for women are warranted.

Our study had some limitations. First, this study included only Korean participants; thus, our findings cannot be generalised to other populations. A multi-ethnic study is required to confirm our findings, especially focusing on physical function. Second, although we calculated the optimal cut-off values of anthropometric indices for the diagnosis of sarcopenic obesity, we could not validate these findings with other scientific evidence as the attempt to apply anthropometric indices to diagnose sarcopenic obesity has not been utilised broadly in the clinical field. It is necessary to establish an appropriate cut-off value for the diagnosis

of sarcopenic obesity in clinical practice. Third, the age range of our study was set from 70 to 84 years. We were not able to provide a result for older adults aged 85 years or older; the recruitment of participants with higher ages can be more valuable for this study as the prevalence of sarcopenic obesity increases with age. Finally, this study had a cross-sectional design and causal relationships could not be established; longitudinal studies are required to identify the causal relationship between the anthropometric indices and sarcopenic obesity.

In conclusion, WWI showed the strongest association with three different definitions of sarcopenic obesity and was the best screening tool compared with WHtR, WC and BMI in older men. No anthropometric indices were associated with any definition of sarcopenic obesity in older women. WWI was the only index that was negatively correlated with physical function in both sexes. It has the potential to be utilised as a simple screening tool in clinical practice; however, further research into the sex-specific differences is warranted.

Acknowledgements

The authors thank all the participants and the staff of the Korean Frailty and Aging Cohort Study.

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI15C3153) and the Research Program funded by the National Institute of Health, Korea Disease Control and Prevention Agency (2021-ER0605-00).

Conceptualisation: J. E. K., J. C., M. K., C. W. W.; methodology: J. E. K., J. C., M. K., C. W. W.; formal analysis: J. C.; writing – original draft: J. E. K.; writing – review & editing: J. C., M. K., C. W. W.; supervision: M. K., C. W. W.; project administration: C. W. W.

No potential conflict of interest relevant to this article was reported.

Supplementary material

For supplementary material/s referred to in this article, please visit <https://doi.org/10.1017/S0007114522001817>.

Reference

1. Batsis JA & Villareal DT (2018) Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. *Nat Rev Endocrinol* **14**, 513–537.
2. Rolland Y, Lauwers-Cances V, Cristini C, *et al.* (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'Osteoporose) Study. *Am J Clin Nutr* **89**, 1895–1900.
3. Wannamethee SG, Shaper AG, Lennon L, *et al.* (2007) Decreased muscle mass and increased central adiposity are independently related to mortality in older men. *Am J Clin Nutr* **86**, 1339–1346.

4. Zamboni M, Mazzali G, Fantin F, *et al.* (2008) Sarcopenic obesity: a new category of obesity in the elderly. *Nutr Metab Cardiovasc Dis* **18**, 388–395.
5. Baumgartner RN (2000) Body composition in healthy aging. *Ann N Y Acad Sci* **904**, 437–448.
6. Baumgartner RN, Koehler KM, Gallagher D, *et al.* (1998) Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* **147**, 755–763.
7. Buckinx F, Landi F, Cesari M, *et al.* (2018) Pitfalls in the measurement of muscle mass: a need for a reference standard. *J Cachexia Sarcopenia Muscle* **9**, 269–278.
8. Choi KM (2016) Sarcopenia and sarcopenic obesity. *Korean J Intern Med* **31**, 1054–1060.
9. WHO (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. *World Health Organ Tech Rep Ser* **854**, 1–452.
10. Browning LM, Hsieh SD & Ashwell M (2010) A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. *Nutr Res Rev* **23**, 247–269.
11. Cornier MA, Despres JP, Davis N, *et al.* (2011) Assessing adiposity: a scientific statement from the American Heart Association. *Circulation* **124**, 1996–2019.
12. Nguyen NT, Magno CP, Lane KT, *et al.* (2008) Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. *J Am Coll Surg* **207**, 928–934.
13. Wilson PW, D'Agostino RB, Sullivan L, *et al.* (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med* **162**, 1867–1872.
14. Hainer V & Aldhoon-Hainerova I (2013) Obesity paradox does exist. *Diabetes Care* **36**, S276–S281.
15. Kim NH, Lee J, Kim TJ, *et al.* (2015) Body Mass Index and Mortality in the general population and in subjects with chronic disease in Korea: a nationwide cohort study (2002–2010). *PLOS ONE* **10**, e0139924.
16. Uretsky S, Messerli FH, Bangalore S, *et al.* (2007) Obesity paradox in patients with hypertension and coronary artery disease. *Am J Med* **120**, 863–870.
17. Jackson AS, Stanforth PR, Gagnon J, *et al.* (2002) The effect of sex, age and race on estimating percentage body fat from body mass index: the Heritage Family Study. *Int J Obes Relat Metab Disord* **26**, 789–796.
18. Okorodudu DO, Jumean MF, Montori VM, *et al.* (2010) Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. *Int J Obes* **34**, 791–799.
19. Kuk JL, Katzmarzyk PT, Nichaman MZ, *et al.* (2006) Visceral fat is an independent predictor of all-cause mortality in men. *Obesity* **14**, 336–341.
20. Zhang C, Rexrode KM, van Dam RM, *et al.* (2008) Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. *Circulation* **117**, 1658–1667.
21. Song X, Jousilahti P, Stehouwer CDA, *et al.* (2015) Cardiovascular and all-cause mortality in relation to various anthropometric measures of obesity in Europeans. *Nutrition, Metab Cardiovasc Dis* **25**, 295–304.
22. Christakoudi S, Tsilidis KK, Muller DC, *et al.* (2020) A Body Shape Index (ABSI) achieves better mortality risk stratification than alternative indices of abdominal obesity: results from a large European cohort. *Sci Rep* **10**, 14541.
23. Park Y, Kim NH, Kwon TY, *et al.* (2018) A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality. *Sci Rep* **8**, 16753.
24. Kim NH, Park Y, Kim NH, *et al.* (2021) Weight-adjusted waist index reflects fat and muscle mass in the opposite direction in older adults. *Age Ageing* **50**, 780–786.
25. Chen LK, Woo J, Assantachai P, *et al.* (2020) Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. *J Am Med Dir Assoc* **21**, 300–307.e302.
26. Cruz-Jentoft AJ, Bahat G, Bauer J, *et al.* (2019) Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* **48**, 16–31.
27. Fielding RA, Vellas B, Evans WJ, *et al.* (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc* **12**, 249–256.
28. Studenski SA, Peters KW, Alley DE, *et al.* (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* **69**, 547–558.
29. Ling CHY, Meskers CGM & Maier AB (2021) Can anthropometric measures be used as proxies for body composition and physical function in geriatric outpatients? *Arch Gerontol Geriatr* **94**, 104379.
30. Woo J, Leung J & Kwok T (2007) BMI, body composition, and physical functioning in older adults. *Obesity* **15**, 1886–1894.
31. Morley JE, Vellas B, van Kan GA, *et al.* (2013) Frailty consensus: a call to action. *J Am Med Dir Assoc* **14**, 392–397.
32. Kim M, Shinkai S, Murayama H, *et al.* (2015) Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body composition in a community-dwelling older population. *Geriatr Gerontol Int* **15**, 1013–1022.
33. Giangregorio LM & ebbert CE (2003) Effects of metal implants on whole-body dual-energy x-ray absorptiometry measurements of bone mineral content and body composition. *Can Assoc Radiol J* **54**, 305–309. quiz 270–301.
34. Won CW, Lee S, Kim J, *et al.* (2020) Korean frailty and aging cohort study (KFACS): cohort profile. *BMJ Open* **10**, e035573.
35. Ashwell M, Gunn P & Gibson S (2012) Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obes Rev* **13**, 275–286.
36. Kim M, Won CW & Kim M (2018) Muscular grip strength normative values for a Korean population from the Korea National Health and Nutrition Examination Survey, 2014–2015. *PLoS One* **13**, e0201275.
37. Kim M & Won CW (2019) Combinations of gait speed testing protocols (automatic *v.* manual timer, dynamic *v.* static start) can significantly influence the prevalence of slowness: results from the Korean Frailty and Aging Cohort Study. *Arch Gerontol Geriatr* **81**, 215–221.
38. Guralnik JM, Simonsick EM, Ferrucci L, *et al.* (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* **49**, M85–M94.
39. Guralnik JM, Ferrucci L, Pieper CF, *et al.* (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. *J Gerontol Ser A, Biol Sci Med Sci* **55**, M221–231.
40. Ho-Pham LT, Campbell LV & Nguyen TV (2011) More on body fat cutoff points. *Mayo Clin Proc* **86**, 584. author reply 584–585.





41. Baumgartner RN, Wayne SJ, Waters DL, *et al.* (2004) Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. *Obes Res* **12**, 1995–2004.
42. DeLong ER, DeLong DM & Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biom* **44**, 837–845.
43. Peduzzi P, Concato J, Kemper E, *et al.* (1996) A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol* **49**, 1373–1379.
44. Koster A, Leitzmann MF, Schatzkin A, *et al.* (2008) Waist circumference and mortality. *Am J Epidemiol* **167**, 1465–1475.
45. Snijder MB, van Dam RM, Visser M, *et al.* (2006) What aspects of body fat are particularly hazardous and how do we measure them? *Int J Epidemiol* **35**, 83–92.
46. Flegal KM, Shepherd JA, Looker AC, *et al.* (2009) Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. *Am J Clin Nutr* **89**, 500–508.
47. Wang C, Hou XH, Zhang ML, *et al.* (2010) Comparison of body mass index with body fat percentage in the evaluation of obesity in Chinese. *Biomed Environ Sci* **23**, 173–179.
48. Schragger MA, Metter EJ, Simonsick E, *et al.* (2007) Sarcopenic obesity and inflammation in the InCHIANTI study. *J Appl Physiol* **102**, 919–925.
49. Stenholm S, Alley D, Bandinelli S, *et al.* (2009) The effect of obesity combined with low muscle strength on decline in mobility in older persons: results from the InCHIANTI study. *Int J Obes* **33**, 635–644.
50. Ley CJ, Lees B & Stevenson JC (1992) Sex- and menopause-associated changes in body-fat distribution. *Am J Clin Nutr* **55**, 950–954.
51. Schorr M, Dichtel LE, Gerweck AV, *et al.* (2018) Sex differences in body composition and association with cardio-metabolic risk. *Biol Sex Differ* **9**, 28.
52. Goodpaster BH, Carlson CL, Visser M, *et al.* (2001) Attenuation of skeletal muscle and strength in the elderly: the Health ABC Study. *J Appl Physiol* **90**, 2157–2165.
53. Visser M, Goodpaster BH, Kritchevsky SB, *et al.* (2005) Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. *J Gerontol A Biol Sci Med Sci* **60**, 324–333.
54. Beavers KM, Beavers DP, Houston DK, *et al.* (2013) Associations between body composition and gait-speed decline: results from the Health, Aging, and Body Composition study. *Am J Clin Nutr* **97**, 552–560.
55. Kim JY, Choi J, Vella CA, *et al.* (2022) Associations between Weight-adjusted waist index and abdominal fat and muscle mass: multi-ethnic study of atherosclerosis. *Diabetes Metab J* (online ahead of print).
56. Kim JH, Choi SH, Lim S, *et al.* (2013) Sarcopenia and obesity: gender-different relationship with functional limitation in older persons. *J Korean Med Sci* **28**, 1041–1047.